Bringing UC Clinical Decision-Making into Focus for 2020: Identify the Right Treatment for the Right Patient at the Right Time

The management of ulcerative colitis (UC) is evolving. In the last 2 years, the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG) released updated, evidence-based treatment guidelines with recommendations for disease stratification, prognosis, treatment options, and disease monitoring. Additionally, new efficacy, safety, and comparative effectiveness data from advanced treatment options are now available, and the list is expected to grow with the approval of additional therapies in the future.

In this CME Outfitters live virtual symposium, expert faculty will compare the new AGA and ACG guideline recommendations and discuss recent clinical trial and real-world data in order to provide learners with recommendations on selecting the appropriate therapy for individual patients. In addition, faculty will discuss proven strategies to empower, educate, and engage patients in their UC care.

At the end of this CE activity, participants should be able to:
-Compare new AGA and ACG guideline recommendations on the treatment of UC in order to identify the appropriate course of action for individual patients.
-Differentiate targeted therapies for UC using efficacy, safety, and comparative effectiveness data from clinical trials and real-world experience.
-Empower and educate patients to become an active part of SDM.

The following learning objectives pertain only to those requesting CNE or CPE credit:
-Compare new AGA and ACG guideline recommendations on the treatment of UC in order to identify the appropriate course of action for individual patients.
-Differentiate targeted therapies for UC using efficacy, safety, and comparative effectiveness data from clinical trials and real-world experience.
-Describe ways to empower and educate patients to become an active part of SDM.